Free Trial

NIOX Group (NIOX) Competitors

NIOX Group logo
GBX 75.77 +1.37 (+1.85%)
As of 03/28/2025 12:41 PM Eastern

NIOX vs. SN, MXCT, EKF, CREO, IUG, NCYT, POLX, IHC, AVO, and MHC

Should you be buying NIOX Group stock or one of its competitors? The main competitors of NIOX Group include Smith & Nephew (SN), MaxCyte (MXCT), EKF Diagnostics (EKF), Creo Medical Group (CREO), Intelligent Ultrasound Group (IUG), Novacyt (NCYT), Polarean Imaging (POLX), Inspiration Healthcare Group (IHC), Advanced Oncotherapy (AVO), and MyHealthChecked (MHC). These companies are all part of the "medical devices" industry.

NIOX Group vs.

NIOX Group (LON:NIOX) and Smith & Nephew (LON:SN) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, community ranking, institutional ownership, media sentiment, valuation, dividends, earnings and profitability.

NIOX Group has a net margin of 28.21% compared to Smith & Nephew's net margin of 5.41%. NIOX Group's return on equity of 13.29% beat Smith & Nephew's return on equity.

Company Net Margins Return on Equity Return on Assets
NIOX Group28.21% 13.29% 3.95%
Smith & Nephew 5.41%5.85%4.51%

Smith & Nephew has a consensus target price of GBX 4,607.50, indicating a potential upside of 330.21%. Given Smith & Nephew's stronger consensus rating and higher possible upside, analysts plainly believe Smith & Nephew is more favorable than NIOX Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NIOX Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Smith & Nephew
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

35.2% of NIOX Group shares are held by institutional investors. Comparatively, 62.2% of Smith & Nephew shares are held by institutional investors. 46.7% of NIOX Group shares are held by insiders. Comparatively, 0.2% of Smith & Nephew shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

NIOX Group has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500. Comparatively, Smith & Nephew has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500.

NIOX Group has higher earnings, but lower revenue than Smith & Nephew. Smith & Nephew is trading at a lower price-to-earnings ratio than NIOX Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NIOX Group£3.53B8.81£995.88M£0.023,127.06
Smith & Nephew£7.08B1.66£382.79M£27.7738.56

Smith & Nephew received 559 more outperform votes than NIOX Group when rated by MarketBeat users. However, 100.00% of users gave NIOX Group an outperform vote while only 62.02% of users gave Smith & Nephew an outperform vote.

CompanyUnderperformOutperform
NIOX GroupOutperform Votes
1
100.00%
Underperform Votes
No Votes
Smith & NephewOutperform Votes
560
62.02%
Underperform Votes
343
37.98%

In the previous week, Smith & Nephew had 2 more articles in the media than NIOX Group. MarketBeat recorded 5 mentions for Smith & Nephew and 3 mentions for NIOX Group. Smith & Nephew's average media sentiment score of 1.44 beat NIOX Group's score of 0.10 indicating that Smith & Nephew is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
NIOX Group
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Smith & Nephew
3 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

NIOX Group pays an annual dividend of GBX 1 per share and has a dividend yield of 1.3%. Smith & Nephew pays an annual dividend of GBX 29 per share and has a dividend yield of 2.7%. NIOX Group pays out 4,126.8% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Smith & Nephew pays out 104.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Smith & Nephew is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

Smith & Nephew beats NIOX Group on 12 of the 20 factors compared between the two stocks.

Remove Ads
Get NIOX Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for NIOX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NIOX vs. The Competition

MetricNIOX GroupMedical Devices IndustryMedical SectorLON Exchange
Market Cap£31.12B£3.55B£5.63B£2.60B
Dividend Yield1.66%2.44%4.57%4.82%
P/E Ratio3,127.0679.2323.33141.07
Price / Sales8.81130.76387.54282,128.95
Price / Cash11.2115.9938.1627.97
Price / Book4.203.806.894.61
Net Income£995.88M£126.02M£3.20B£5.79B
7 Day Performance2.67%-3.60%-2.98%1.39%
1 Month Performance20.66%-6.79%1.63%7.30%
1 Year Performance18.40%-12.26%9.44%112.11%

NIOX Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NIOX
NIOX Group
N/AGBX 75.77
+1.8%
N/A+18.4%£31.12B£3.53B3,127.0692
SN
Smith & Nephew
3.9894 of 5 stars
GBX 1,105.50
+1.1%
GBX 4,607.50
+316.8%
+2.3%£12.12B£7.08B39.8018,452Insider Trade
News Coverage
High Trading Volume
MXCT
MaxCyte
N/AGBX 245
-2.0%
N/A-35.8%£323.41M£57.52M-8.9880
EKF
EKF Diagnostics
N/AGBX 19.95
+3.4%
N/A-20.7%£88.67M£49.91M18.57356Earnings Report
Insider Trade
News Coverage
Positive News
High Trading Volume
CREO
Creo Medical Group
N/AGBX 13
+1.0%
N/A-62.2%£52.56M£33.87M-2.06279News Coverage
IUG
Intelligent Ultrasound Group
N/AN/AN/AN/A£42.76M£6.57M-18.9165
NCYT
Novacyt
N/AGBX 46.90
-3.9%
N/A-6.8%£32.41M£18.12M-0.86120
POLX
Polarean Imaging
N/AGBX 1.21
-1.0%
N/A-73.2%£17.80M£5.21M-0.3128
IHC
Inspiration Healthcare Group
N/AGBX 17
+3.0%
N/A-41.8%£14.73M£42.87M-1.17224Positive News
Gap Down
AVO
Advanced Oncotherapy
N/AN/AN/AN/A£9.50MN/A-25.003,900Gap Down
MHC
MyHealthChecked
N/AGBX 16
+5.6%
N/A+17.9%£8.33M£9.43M-7.9816Gap Down
Remove Ads

Related Companies and Tools


This page (LON:NIOX) was last updated on 3/29/2025 by MarketBeat.com Staff
From Our Partners